Arcellx (ACLX) Total Non-Current Liabilities (2021 - 2025)
Arcellx's quarterly Total Non-Current Liabilities came in at $201.6 million in Q4 2025, down 18.67% year-on-year from $247.9 million in Q4 2024, and down 6.28% quarter-over-quarter from $215.1 million in Q3 2025.
Arcellx has reported Total Non-Current Liabilities for 4 years, with the latest figure at $201.6 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 18.67% year-over-year to $201.6 million; the trailing twelve-month figure through Dec 2025 stood at $201.6 million (down 18.67% YoY), and the FY2025 full-year result was $201.6 million, down 18.67% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $201.6 million, down from $215.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $267.7 million in Q1 2024, with the low at $16.7 million in Q4 2021.
- Average Total Non-Current Liabilities over 4 years is $179.3 million, with a median of $226.9 million recorded in 2025.
- Peak annual rise in Total Non-Current Liabilities reached 2.32% in 2025, while the deepest fall reached 19.38% in 2025.
- Tracing ACLX's Total Non-Current Liabilities over 4 years: stood at $16.7 million in 2021, then soared by 204.22% to $50.9 million in 2022, then jumped by 386.86% to $247.9 million in 2024, then fell by 18.67% to $201.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $201.6 million (Q4 2025), $215.1 million (Q3 2025), and $226.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 201.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 201.64 Mn |
| Sep 30, 2025 | 215.14 Mn |
| Jun 30, 2025 | 226.86 Mn |
| Mar 31, 2025 | 227.74 Mn |
| Dec 31, 2024 | 247.94 Mn |
| Sep 30, 2024 | 266.84 Mn |
| Jun 30, 2024 | 232.24 Mn |
| Mar 31, 2024 | 267.65 Mn |
| Jun 30, 2022 | 50.93 Mn |
| Mar 31, 2022 | 18.90 Mn |
| Dec 31, 2021 | 16.74 Mn |